Novartis Chief Commits To Sandoz And Its German Headquarters
Novartis has no plans to sell Sandoz, nor to move the generics division’s headquarters from its current location in Holzkirchen, Germany. Legacy German brand Hexal also remains part of the company’s plans.
You may also be interested in...
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.